- Home
- HHS vs DYAI Comparison
HHS vs DYAI Comparison
Compare HHS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- DYAI
- Stock Information
- Founded
- HHS 1923
- DYAI 1979
- Country
- HHS United States
- DYAI United States
- Employees
- HHS N/A
- DYAI N/A
- Industry
- HHS Advertising
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HHS Consumer Discretionary
- DYAI Health Care
- Exchange
- HHS Nasdaq
- DYAI Nasdaq
- Market Cap
- HHS 30.3M
- DYAI 28.3M
- IPO Year
- HHS N/A
- DYAI 2004
- Fundamental
- Price
- HHS $3.38
- DYAI $0.98
- Analyst Decision
- HHS
- DYAI Strong Buy
- Analyst Count
- HHS 0
- DYAI 1
- Target Price
- HHS N/A
- DYAI $6.00
- AVG Volume (30 Days)
- HHS 29.6K
- DYAI 64.2K
- Earning Date
- HHS 08-07-2025
- DYAI 08-12-2025
- Dividend Yield
- HHS N/A
- DYAI N/A
- EPS Growth
- HHS N/A
- DYAI N/A
- EPS
- HHS N/A
- DYAI N/A
- Revenue
- HHS $181,355,000.00
- DYAI $3,554,344.00
- Revenue This Year
- HHS $6.54
- DYAI $22.56
- Revenue Next Year
- HHS N/A
- DYAI $30.95
- P/E Ratio
- HHS N/A
- DYAI N/A
- Revenue Growth
- HHS N/A
- DYAI 57.59
- 52 Week Low
- HHS $3.24
- DYAI $0.91
- 52 Week High
- HHS $8.52
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- HHS 32.45
- DYAI 49.96
- Support Level
- HHS $3.70
- DYAI $0.91
- Resistance Level
- HHS $4.03
- DYAI $1.02
- Average True Range (ATR)
- HHS 0.37
- DYAI 0.05
- MACD
- HHS -0.01
- DYAI 0.01
- Stochastic Oscillator
- HHS 0.00
- DYAI 46.80
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.